• 1.

    Rojas-Rivera JE, et al. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J 2019; 12:629638. doi: 10.1093/ckj/sfz127

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Singh L, et al. Understanding podocytopathy and its relevance to clinical nephrology. Indian J Nephrol 2015; 25:17. doi: 10.4103/0971-4065.134531

  • 3.

    Ferreira F, Nunes AT. New treatments in membranous glomerulopathy—from the pitfalls of rituximab to a new era of biological treatments. Port J Nephrol Amp Hypertens 2020; 34:160164. http://doi.org/10.32932/pjnh.2020.10.087

    • Search Google Scholar
    • Export Citation
  • 4.

    Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:16171630. doi: 10.1681/ASN.2012010058

  • 5.

    Salvadori M, Tsalouchos A. Editor’s pick: New aspects of pathogenesis and treatment of membranous glomerulopathy after the MENTOR study. EMJ Nephrol 2020; 8:4653. https://www.emjreviews.com/nephrology/article/editors-pick-new-aspects-of-pathogenesis-and-treatment-of-membranous-glomerulopathy-after-the-mentor-study/

    • Search Google Scholar
    • Export Citation
  • 6.

    Fervenza FC, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:3646. doi: 10.1056/NEJMoa1814427

  • 7.

    Delbarba E, et al. Rituximab vs. cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. American Society of Nephrology, Kidney Week. October 22, 2020; PO2638. Accessed December 21, 2020. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3470922

    • Search Google Scholar
    • Export Citation
  • 8.

    Fernández-Juárez G, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [Published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.kidney-international.org/article/S0085-2538(20)31251-5/fulltext

    • Search Google Scholar
    • Export Citation
  • 9.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Rituximab plus cyclosporine in idiopathic membranous nephropathy. ClinicalTrials.gov: NCT00977977. Accessed December 20, 2020. https://clinicaltrials.gov/ct2/show/NCT00977977

    • Search Google Scholar
    • Export Citation
  • 10.

    Klomjit N, et al. Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: A report of 3 cases. Am J Kidney Dis 2020; 76:883888. doi: 10.1053/j.ajkd.2020.02.444

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Sethi S, et al. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 2020; 5:15151518. doi: 10.1016/j.ekir.2020.06.030

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377:13311344. doi: 10.1056/NEJMoa1614598

  • 13.

    Hoffmann-La Roche. A phase III randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy. ClinicalTrials.gov: NCT04629248. Accessed December 29, 2020. https://clinicaltrials.gov/ct2/show/NCT04629248

    • Search Google Scholar
    • Export Citation

Rituximab and Obinutuzumab for Membranous Nephropathy

  • 1 Sahar Semnani, MD, MBA, is a nephrology fellow at the Keck School of Medicine of the University of Southern California, Los Angeles, CA. Eugene Lin, MD, MS, FASN, is an Assistant Professor of Medicine and of Health Policy & Management at the Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Restricted access
Save